Journals / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2012 / Cilt: 25 - Sayı: 1

Nöroleptik malign sendrom gelişiminde demografik ve klinik risk etkenlerinin araştırılması: Literatürdeki Türkçe olguların değerlendirilmes

Detection of demografic and clinical risk factors associated with neuroleptic malignant syndrome: Evaluation of cases in the Turkish literature

Pages
35–42
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Detecting the risk factors for NMS would help clinicians prevent probable complications of NMS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Detection of demografic and clinical risk factors associated with neuroleptic malignant syndrome: evaluation of cases in the Turkish literature Objective: Neuroleptic malignant syndrome (NMS) is a severe adverse effect which can be seen during antipsycotic treatment.
📊
Key Findings & Data:Methods: Twenty-one out of 22 articles which were published in 2010 and before and full texts were accessed by cross referencing after scanning NMS key words at Turkish Psychiatry Index were included in this study.
💡
Conclusion & Impact:Detecting the risk factors for NMS would help clinicians prevent probable complications of NMS.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Detection of demografic and clinical risk factors associated with neuroleptic malignant syndrome: evaluation of cases in the Turkish literature Objective: Neuroleptic malignant syndrome (NMS) is a severe adverse effect which can be seen during antipsycotic treatment. The aim of this study was to evaluate the demographics, clinical features, psychiatric diagnoses, laboratory findings, treatment and complications of NMS cases reported in the Turkish literature. Methods: Twenty-one out of 22 articles which were published in 2010 and before and full texts were accessed by cross referencing after scanning NMS key words at Turkish Psychiatry Index were included in this study. Clinical and laboratory findings, treatments and developing complications of 32 cases were evaluated. Results: Thirty-two patients with a mean age of 27.3±12 years were identified. 40.7% of the cases were diagnosed with schizophrenia or other psychotic disorders while 34.4% were diagnosed with bipolar disorders. Rigidity, disturbances of consciousness, fever, sweating were present in most of the NMS cases. Sixteen (50%) NMS cases were taking classical antipsychotics while 4 (12.5%) of them were taking atypical antipsychotics during the diagnosis of NMS. The most common treatment choices for NMS were bromocriptine, electroconvulsive therapy and dantrolene. Aspiration pneumonia and acute renal failure were the most common complications due to NMS. It was reported that 6.3% (n= 2) of the cases died. Conclusion: It was remarkable that the mean antipsychotic dosages in MNS cases were within therapeutic limits. Detecting the risk factors for NMS would help clinicians prevent probable complications of NMS.

Özet

Amaç: Nöroleptik malign sendrom (NMS), antipsikotik kullanımı sırasında görülebilen ciddi bir yan etkidir. Bu çalışmanın amacı, NMS tanısıyla bildirilen Türkçe olguları demografik özellikler, klinik bulgular, laboratuvar değerleri, tedavi ve gelişen komplikasyonlar açısından değerlendirmek ve klinisyenlere gündelik pratikte yardımcı veriler sağlamaktır. Yöntem: Bu çalışmaya, 2010 yılında ve öncesinde yayımlanmış olan ve Türk Psikiyatri Dizini’nde NMS anahtar kelimeleriyle yapılan tarama sonrasında tam metnine çapraz referanslama yoluyla ulaşılan 22 makaleden 21’i dahil edilmiştir. Bu makalelerden ulaşılan 32 olgu; klinik bulgular, laboratuvar değerleri, tedavi ve gelişen komplikasyonlar açısından değerlendirilmiştir. Bulgular: Yaş ortalaması 27.3±12 olarak belirlenen olguların %40.7’sinin şizofreni ve diğer psikotik bozukluklar, %34.4’ünün ise bipolar bozukluk tanısı ile takip edildiği saptanmıştır. Rijidite, bilinç değişikliği, ateş, terleme olguların çoğunluğunda tabloya eşlik etmekteydi. NMS bulgularının, 16 (%50.0) olguda sadece tipik antipsikotik tedavi alırken, 4 (%12.5) olguda ise sadece atipik antipsikotik tedavi alırken geliştiği gözlendi. NMS tedavisinde en sık tercih edilen seçenekler bromokriptin, EKT ve dantrolendi. NMS’ye bağlı en sık gelişen komplikasyonlar ise, aspirasyon pnömonisi ve akut böbrek yetmezliğiydi. Olguların % 6.3’ünün (n=2) yaşamını yitirdiği bildirilmişti. Sonuç: NMS tanısı konduğu sırada kullanılmakta olan antipsikotik ilaç dozlarının terapötik aralıkta saptanması dikkat çekicidir. NMS’nin ortaya çıkışında risk etkenlerinin belirlenmesi, klinisyenlerin olası komplikasyonları engellemede erken önlem almasını sağlayacaktır

🔖

Cite This Article

ALKAN, F., ALTINBAŞ, K. (2012). Nöroleptik malign sendrom gelişiminde demografik ve klinik risk etkenlerinin araştırılması: Literatürdeki Türkçe olguların değerlendirilmes. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 25 - Sayı: 1, 35–42. https://ajindex.com/articles/215696

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Delay J, Pichot P, Lempiere T, Blissalde B, Peigne F. Un neuroleptique majeur non phenothiazinique et non reserpinique, l’haloperidol, dans le traitement des psychoses. (A non phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses). Ann Med Psychol 1960; 18:145- 152
  2. Jahan MS, Farooque AI, Wahid Z. The neuroleptic malignant syndrome. J Natl Med Assoc 1992; 84:966-970
  3. Pelonero AL, Levenson JL, Pandurangi KA. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49:1163–1172
  4. Bottoni TN. Neuroleptic malignant syndrome: a brief review. Hosp Physician 2002; 38:58-63
  5. Steele D, Keltner NL, McGuiness TM. Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome? Perspect Psychiatr Care 2011; 47:58-62
  6. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870-876
  7. Nishijima K, Ishiguro T. Clinical course and CSF monoamine metabolism in neuroleptic malignant syndrome: a study of nine typical cases and five mild cases. Seishin Shinkeigaku Zasshi 1989; 91:429-456
  8. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156:169-180
  9. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001; 72:325-336
  10. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85:129-135
  11. Kaplan HI, Sadock BJ, Grebb JA. Kaplan&Sadock’s Comprehensive Textbook of Psychiatry. Eighth ed. Philadelphia: Lipincott Williams & Wilkins, 2005, 923
  12. Van Agtmael MA, Van Harten PN. Malignant neuroleptic syndrome: complete anticoagulant treatment or not? Ned Tijdschr Geneeskd 1992; 136:1870-1872
  13. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1986; 142:1137-1145. 14. www.psikiyatridizini.org (Database of Turkish Pyschiatric Literature)
  14. Kamışlı Ö, Özcan Ö, Kaplan Y, Özcan C. Ergen hastada aripiprazole bağlı nöroleptik malign sendrom: Bir olgu sunumu. Nöropsikiyatri Arşivi 2010; 47:260-262 (Article in Turkish)
  15. Kalenderoğlu A, Cansel N, Selek S, Savaş HA. Tek doz olanzapin enjeksiyonu uygulaması sonrası gelişen nöroleptik malign sendrom: Olgu sunumu. Klinik Psikiyatri Dergisi 2006; 9:99-102 (Article in Turkish)
  16. Canbek Ö, Sevim ME, Öncü F, Soysal H. Neuroleptic malignant syndrome: a case treated with bromocriptine. Düşünen Adam: The Journal Of Psychiatry and Neurological Sciences 2010; 23:210-214
  17. Tomruk NB,